Synthesis of New Polymeric Composite Materials Derived from 2,2-(1,6-Dioxohexane-1,6-diyl) Dihydrazinecarbothioamide
نویسندگان
1 Department of Chemistry, College of Education for Pure Science(Ibn Al-Haitham), University of Baghdad, Iraq
2 Department of Chemistry, College of Education for Pure Science(Ibn Al-Haitham), University of Baghdad, Iraq
3 Department of Chemistry, College of Education for Pure Science(Ibn Al-Haitham), University of Baghdad, Iraq
4 Department of Chemistry, College of Education for Pure Science(Ibn Al-Haitham), University of Baghdad, Iraq
doi
10.22052/JNS.2026.02.048چکیده
In this study, a new class of polymeric nanocomposites was synthesized and characterized. One mole of dimethyl adipate and two moles of thiosemicarbazide in ethanol first reacted to form the compound [C1]. Compound [C1] then reacted with sodium hydroxide to produce compounds [C2]. Hydrazine hydrate reacted with compound [C2] to generate compound [C3]. Compound [C4] was synthesized from compound [C3] and maleic anhydride. A polymer [C5] is formed by the reaction of the compound [C4] with ammonium persulfate as an initiator. This polymer was then combined with nano: ZnNPs, AgNPs, SiNPs, or IONPs using a hotplate stirrer for 3 hours to produce nanocomposites [C6-C9]. FTIR, 1H-NMR, and Field Emission Scanning Electron Microscope (FESEM) were among the spectral analysis techniques used to identify the synthesized compounds. Investigations were also conducted into the thermal properties of TGA and DSC. Molecular docking was studied to evaluate the prepared compounds’ free energy (ΔG) and predict their binding status with the enzyme. Lastly, examine the biological activities of polymers and nanocomposites that were screened using Bacillus cereus and Escherichia coli, as well as their anti-cancer activity against the human liver cancer cell line HepG2, using the normal cell line WRL68 as a comparison. In conclusion, the encouraging anticancer activities of the newly prepared nanocomposites induce more preclinical examination to move to clinical use in due course.